Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus RESNIBEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE AND HYDROCHLOROTHIAZIDE versus RESNIBEN.
HYDRALAZINE AND HYDROCHLOROTHIAZIDE vs RESNIBEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting smooth muscle vasodilator that relaxes arterioles, reducing peripheral resistance. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Oral: 1 tablet (hydralazine 25 mg / hydrochlorothiazide 25 mg) 1-2 times daily. Maximum: hydralazine 200 mg/day, hydrochlorothiazide 50 mg/day.
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); extended in renal impairment. Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min).
Hydralazine: 80-90% renal (mostly as metabolites), <10% unchanged. Hydrochlorothiazide: 95-99% renal (unchanged).
Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic